Tag: managers

BOSTON, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

MALVERN, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- CubeSmart (NYSE: CUBE) (the “Company” or “CubeSmart”), the third-largest owner and operator of self-storage properties in the United States, today announced that its operating partnership, CubeSmart, L.P. (the “Operating Partnership”), priced an offering of $450.0 million aggregate principal amount of 5.125% senior unsecured notes due 2035 (the “Notes”) in an underwritten public offering. The Notes were priced at 98.656% of the principal amount with a yield to maturity of 5.295%. The Notes will be fully and unconditionally guaranteed by CubeSmart. The offering is expected to close on August 20, 2025, subject to the satisfaction of customary closing conditions.

MOUNTAIN VIEW, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), a leader in AI technology for coronary artery disease (CAD), today announced the closing of its upsized initial public offering of 19,166,667 shares of its common stock at a public offering price of $19 per share, which includes 2,500,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. All of the shares of common stock were offered by Heartflow. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Heartflow, were approximately $364.2 million. Heartflow’s common stock began trading on the Nasdaq Global Select Market on August 8, 2025 under the ticker symbol “HTFL.”

DALLAS, Aug. 11, 2025 (GLOBE NEWSWIRE) -- HF Sinclair Corporation (NYSE and NYSE Texas: DINO) (the “Corporation”) today announced that it has commenced a cash tender offer (the “Tender Offer”) to purchase any and all of the outstanding notes listed in the table below (collectively, the “Notes” and each a “Series” of Notes).

LONDON, Aug. 11, 2025 (GLOBE NEWSWIRE) -- ATFX Connect, the institutional arm of ATFX, is pleased to announce the appointment of Professor Trevor Williams as its Consultant Economist. This strategic move underscores ATFX Connect’s commitment to delivering expert-driven macroeconomic insights and analysis to its growing base of institutional clients.